| Literature DB >> 34966004 |
Luzia Jaeger Hintze1, Ana Claudia Pelissari Kravchychyn1, Yasmin Alaby Martins Ferreira1, Raquel Munhoz da Silveira Campos2, Alexandre D Aguilera Dantas3, Deborah Cristina Landi Masquio4, Danielle Arisa Caranti2, David Thivel5, Ana R Dâmaso1.
Abstract
BACKGROUND: The purpose of the present study was to compare the impact of semi-intensive and intensive interdisciplinary weight-loss therapies on the treatment of metabolic syndrome (MS) and selected inflammatory markers in adolescents with obesity.Entities:
Keywords: Adiponectin; Adolescents; Leptin; Metabolic syndrome; Obesity management; Patient care team; Weight loss
Year: 2021 PMID: 34966004 PMCID: PMC8735820 DOI: 10.7570/jomes21049
Source DB: PubMed Journal: J Obes Metab Syndr ISSN: 2508-6235
Figure 1Study design. BMI, body mass index.
Baseline demographic characteristics of the study population
| Variable | Semi-intensive | Intensive |
|
|---|---|---|---|
| Age (yr) | 17.15 (1.75) | 17.03 (1.67) | 0.723 |
| Baseline BMI | 38.2 (4.54) | 38.3 (5.34) | 0.921 |
| Drop-out | 25 (29) | 29 (36.2) | 0.516 |
| No. of completers | 61 | 51 | 0.064 |
| Female | 31 (51) | 34 (67) | |
| Male | 30 (49) | 17 (33) |
Values are presented as number (%).
BMI, body mass index.
Anthropometric measurement results and body composition at baseline and post intervention in the semi-intensive and intensive groups
| Variable | Semi-intensive (n=61) | Intensive (n=51) | Change within groups ( | Effect size η2 | Change between groups ( | Effect size η2 | ||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
| |||||||||
| Baseline | Postintervention | % Change | Baseline | Postintervention | % Change | |||||
| BW (kg) | 110.99 ± 15.22 | 105.28 ± 14.41 | –5.15 | 107.09 ± 16.31 | 97.11 ± 17.65 | –9.30 | < 0.001 | 0.586 | 0.001 | 0.095 |
| BW z score | 0.11 ± 0.96 | 0.23 ± 0.87 | –0.13 ± 1.03 | –0.27 ± 1.07 | 0.821 | 0.000 | 0.002 | 0.085 | ||
| Height (m) | 1.71 ± 0.09 | 1.71 ± 0.09 | 0.32 | 1.67 ± 0.08 | 1.68 ± 0.08 | 0.28 | < 0.001 | 0.016 | 0.863 | 0.000 |
| Height z score | 0.17 ± 1.02 | 0.17 ± 1.01 | –0.19 ± 0.94 | –0.20 ± 0.96 | 0.992 | 0.000 | 0.885 | 0.000 | ||
| BMI (kg/m2) | 38.21 ± 4.54 | 36.05 ± 4.56 | –5.70 | 38.30 ± 5.34 | 34.54 ± 5.80 | –9.80 | < 0.001 | 0.622 | < 0.001 | 0.107 |
| BMI z-score | –0.01 ± 0.92 | 0.13 ± 0.87 | 0.01 ± 1.09 | –0.15 ± 1.11 | 0.802 | 0.001 | 0.001 | 0.103 | ||
| Fat mass (kg) | 41.99 ± 8.44 | 37.89 ± 7.40 | –9.03 | 51.33 ± 12.61 | 37.96 ± 14.06 | –27.16 | < 0.001 | 0.691 | < 0.001 | 0.387 |
| Lean body mass (kg) | 68.65 ± 10.71 | 67.04 ± 10.38 | –2.26 | 55.55 ± 7.41 | 59.42 ± 9.33 | 6.48 | 0.002 | 0.083 | < 0.001 | 0.348 |
Values are presented as mean± standard deviation.
*Significant differences; effect sizes η2 = 0.010, 0.059, and 0.138 were cut-off points for small, medium, and large effect sizes, respectively.
BW, body weight; BMI, body mass index.
MS risk factors and inflammatory biomarkers at baseline and post intervention in the semi-intensive and intensive groups
| Variable | Semi-intensive (n= 61) | Intensive (n=51) | Change within group ( | Effect size η2 | Change between group ( | Effect size η2 | ||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
| |||||||||
| Baseline | Post-intervention | % Change | Baseline | Post-intervention | % Change | |||||
| SBP (mmHg) | 118.11 ± 9.75 | 119.11 ± 8.50 | 1.31 | 125.85 ± 18.39 | 114.79 ± 7.87 | –6.59 | < 0.001 | 0.622 | < 0.001 | 0.107 |
| DBP (mmHg) | 76.64 ± 6.37 | 76.88 ± 6.71 | 0.70 | 79.15 ± 8.75 | 74.15 ± 5.75 | –6.31 | 0.006 | 0.070 | 0.002 | 0.083 |
| WC (cm) | 109.86 ± 10.09 | 104.97 ± 10.80 | –4.41 | 105.72 ± 11.26 | 95.13 ± 12.06 | –11.00 | < 0.001 | 0.465 | 0.001 | 0.105 |
| Glucose (mg/dL) | 89.62 ± 7.47 | 88.44 ± 7.28 | –0.78 | 90.57 ± 7.77 | 86.76 ± 7.55 | –5.30 | 0.004 | 0.072 | 0.128 | 0.021 |
| HDL-C (mg/dL) | 40.51 ± 8.33 | 43.23 ± 8.28 | 8.08 | 43.55 ± 8.45 | 44.06 ± 9.15 | 3.90 | 0.003 | 0.078 | 0.039 | 0.038 |
| TG (mg/dL) | 127.25 ± 58.41 | 111.25 ± 57.87 | –7.84 | 106.67 ± 75.70 | 88.35 ± 45.70 | –9.76 | 0.002 | 0.083 | 0.832 | 0.000 |
| Adiponectin (mg/dL) | 2.58 ± 1.91 | 3.34 ± 2.93 | 29.45 | 7.20 ± 3.33 | 9.39 ± 4.76 | 30.42 | < 0.001 | 0.215 | 0.010 | 0.061 |
| Leptin (mg/dL) | 64.68 ± 42.40 | 48.35 ± 39.04 | –23.52 | 44.20 ± 30.34 | 29.83 ± 24.70 | –25.27 | < 0.001 | 0.236 | 0.709 | 0.001 |
| Number of MS risk factors | 2.07 ± 0.87 | 1.70 ± 0.76 | –17.90 | 2.12 ± 0.95 | 1.28 ± 0.78 | –39.60 | < 0.001 | 0.317 | 0.005 | 0.069 |
| Adiponectin/leptin | 0.04 (0.07) | 0.08 (0.01) | 66.00 | 0.27 (0.36) | 0.38 (0.54) | 40.00 | 0.714 | |||
Values are presented as mean± standard deviation or median (interquartile range).
*Significant differences; effect sizes η2 = 0.010, 0.059, and 0.138 were cut-off points for small, medium, and large effect sizes, respectively.
MS, metabolic syndrome; SPB, systolic blood pressure; DBP, diastolic blood pressure; WC, waist circumference; HDL-C, high-density lipoprotein cholesterol; TG, triacylglycerol.
Figure 2Metabolic syndrome (MS) factors (A) and prevalence of MS-associated hyperleptinemia (B) in adolescents with obesity. *Significance P<0.05. TG, triacylglycerol; HDL-C, high-density lipoprotein cholesterol; SPB, systolic blood pressure; DBP, diastolic blood pressure; WC, waist circumference.